title: Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.
abstract: Patients with stage II melanoma were vaccinated with vaccinia virus-induced melanoma cell lysates (VMCL). The vaccine contained viable vaccinia virus, membranous fragments and no intact nuclei. A number of antigens defined by monoclonal antibodies were detected in the vaccine including the ganglioside GD3 and DR antigens. Administration of the vaccine was associated with depression of natural killer cell activity against melanoma and K562 target cells in the first 3-6 months of treatment. Leucocyte dependent antibody (LDA) activity against melanoma cells was induced or increased in titre in approximately half of the patients studied. Continued vaccination was associated in a number of patients with a decrease in LDA titres. Studies on a small sample of patients revealed that this was associated with the development of serum factors which inhibited LDA activity. LDA activity appeared directed to non-MHC antigens on melanoma cells which were of at least two specificities. One specificity which was shared with antigens on a number of non-melanoma carcinoma cells was removed by absorption on fetal brain and may be similar to oncofetal antigens described by other workers. Reactivity against melanocytes was induced in some patients and may underline the development of vitiligo in several patients. These results suggest that vaccines prepared from VMCL may be a favourable method for increasing immune responses against melanoma.
authors.forename: P
authors.initials: P
authors.lastname: Hersey
authors.forename: A
authors.initials: A
authors.lastname: Edwards
authors.forename: G
authors.initials: G
authors.lastname: D'Alessandro
authors.forename: M
authors.initials: M
authors.lastname: MacDonald
mesh_terms: D000912:Antibodies, Neoplasm / Q000032:analysis*; D000918:Antibody Specificity; D000956:Antigens, Viral / Q000032:analysis; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D005260:Female; D005732:Gangliosides / Q000032:analysis; D006680:HLA Antigens / Q000276:immunology; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007114:Immunization; D007694:Killer Cells, Natural / Q000276:immunology; D007962:Leukocytes / Q000276:immunology*; D008297:Male; D008545:Melanoma / Q000276:immunology* / Q000628:therapy; D014616:Vaccinia virus / Q000276:immunology*; D014765:Viral Vaccines / Q000032:analysis / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D000956:Antigens, Viral; D005732:Gangliosides; D006680:HLA Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D014765:Viral Vaccines; C019403:ganglioside, GD2